Ann: Change of Director's Interest Notice - M. Washer, page-22

Don't fret about missing out The new CEO won't start until end of May. He won't make any difference for at least 12 months working at the helm. The promised product probably won't be ready by end of June because AusAnn already changed their prediction to "within the 2019 calendar year" and that hints end of the year. Then there has been no work on arrangement for clinical trials. Even if they have the capsules, they will have to set up trials. And then trial will need a lot of time and more time to write reports and more time to be vetted by credible independent organisations/researchers. Papers without peer reviews are pretty much worthless.

You would have saved up cash by the time AC8 turns around and goes up again.

I like to play a dead cat bounce on this stock but now I have second thoughts! I look at a few IPOs from 2017 and the share prices keep grinding lower and lower with a small pop at every new announcements then quickly sold off to new lows. Despite "great announcements" on rapid growth, business development, success of business strategies ..., these companies keep losing more money, burning more cash reserve and getting closer to needing to raise money again. After the big shake-up last Oct, investors are so scared of risk, only companies that have real products and making real profit have share prices going flat or up.